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The serum protein binding secretory prostatic acid phosphatase (PAP) and lysosomal placental acid phos- 
phatase (LAP) was purified using affinity chromatography on gels containing immobilized acid phospha- 
tases. The protein, which could be eluted from these enzyme affinity gels only with 0.05 mol/l HCI (pH 2.0), 
was shown to be apolipoprotein A-I (apo A-I), the main structural protein of high density lipoprotein 
(HDL). 
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1. INTRODUCTION 
Acid phosphatases (EC 3.1.3.2) are widely 
distributed in human body fluids and tissues [I]. 
Prostatic tissue is a rich source of prostatic acid 
phosphatase (PAP), and the concentration of this 
isoenzyme is relatively high in hyperplastic pros- 
tate, approx. 1 mg/g tissue wet wt [2]. PAP is 
also secreted into seminal fluid in concentrations 
of the order of 1 g/l [3], which are 500-1000-fold 
those measurable in peripheral serum of normal 
men [4]. In contrast, another acid phosphatase 
isoenzyme, lysosomal acid phosphatase (LAP), 
purified from placenta, is present in serum in high 
concentrations, about 1 g/l (Vihko et al., in 
preparation). Both these enzymes are inhibited by 
L-( + )-tartrate, but are immunologically distinct 
(Vihko et al., in preparation). The physiological 
roles of these isoenzymes, which hydrolyse a wide 
range of alkyl, aryl and acyl orthophosphate 
monoesters and transfer phosphoryl groups, are 
largely unknown [5]. 
We have previously shown that serum PAP has 
two half-lives, of which one was found to be 
remarkably long, and we suggested that this frac- 
tion may represent PAP bound by serum protein/s 
[4]. The present study was undertaken in order to 
determine the serum protein which binds PAP and 
LAP. 
2. EXPERIMENTAL 
Blood was drawn from the antecubital veins of 
healthy volunteers and patients with carcinoma of 
the prostate. The serum was collected after cen- 
trifugation at 1500 x g for 15 min and was used 
fresh. 
2.1. Enzyme purification 
The main isoenzyme of human PAPS, ~14.9, 
was purified to homogeneity from fresh 
hyperplastic prostatic tissue, as described [6]. LAP 
was isolated from full-term human placental tissue 
by a procedure involving ammonium sulfate frac- 
tionation, affinity chromatography on AH- 
Sepharose 4B with L-( +)-tartrate and Sephadex 
G-200 gel filtration, essentially as described for the 
purification of human PAP [6]. 
2.2. Affinity chromatography 
2.2.1. Preparation of affinity matrices 
The ligands were immobilised on CNBr- 
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activated Sepharose 4B gel (Pharmacia, Sweden) 
according to the instructions of the manufacturer. 
To prepare PAP-Sepharose, 8 mg purified PAP 
was coupled to 2 g activated Sepharose gel. For the 
preparation of LAP-Sepharose, 0.8 mg pure LAP 
was coupled to 0.5 g Sepharose gel. 
When the protein that binds to the acid 
phosphatases was immobilised, 0.3 mg protein and 
400 mg gel were used. 
2.2.2. Procedure 
10 ml serum was incubated with PAP-Sepharose 
at 4°C for 48 h with mixing. The column was 
packed and eluted stepwise with 0.2 M PBS (pH 
7.4), 0.1 M sodium acetate (pH 4.0) and 0.05 M 
HCl (pH 2.0). The protein peak eluted with 0.05 M 
HCl was pooled and used for further studies. In 
experiments with LAP-Sepharose the volume of 
serum used was 1.5 ml. 
2.3. High-performance liquid chromatography 
(HPLC) 
The protein obtained after affinity chroma- 
tography was further purified using a Varian 
model 5000 lipid chromatograph. The sample 
(250 pg protein) in 50 mM Tris-acetate (pH 7.0), 
containing 1 M pyridine and 0.5 M acetic acid, 
was injected onto a Bondapak Cl8 column 
(reverse-phase HPLC, particle size 10 pm, Waters 
Associates, USA). The elution buffers were 0.5 M 
acetic acid (pH 5.4) with 1 M pyridine and 
2-propanol. 
2.4. Antisera 
The antisera against human PAP were raised in 
rabbits as in [7]. The antilysosomal acid 
phosphatase serum has been described [8]. The 
monoclonal antisera against apo A-I used have 
been reported [9]. The antisera against other 
human serum proteins were commercially 
available. 
2.5. Radioimmunoassay of the protein bound by 
acid phosphatases 
The preparation of 12’I-labelled ligand was per- 
formed as in [7]. The radioimmunoassay pro- 
cedure was also performed as described previously 
for PAP [4] with the following exceptions: the 
dilution of antiserum was 1:2000; pre-incubation 
of the specimen and antiserum was for 15 min at 
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20°C before the addition of approx. 30000 cpm 
‘251-labelled bound protein. After overnight in- 
cubation at 20°C the antibody-bound ‘251-labelled 
protein tracer was precipitated with 0.6 ml 
polyethylene glycol-second antibody solution [lo]. 
The standard curve tubes had the following con- 
centrations of the purified non-labelled protein: 0, 
55, 110, 220,440, 880, 1760 fig/ml. Both the stan- 
dards and the samples (1: 2000) were diluted with 
heated (56°C for 30 min) sheep serum diluted with 
an equal volume of sodium phosphate buffer 
(50 mM, pH 7.2) containing 20 mmol EDTA and 
8 mmol NaNJ per 1. 
2.6. Isolation of apo A-I 
Lipoproteins were isolated by sequential 
ultracentrifugation [l 11. Apo A-I was purified as 
described by Albers and Cheung [ 121. 
2.7. Isoelectric focusing and immunoblotting 
Isoelectric focusing of purified acid phospha- 
tase-binding protein and serum was carried out as 
in [ 131. Immunoblotting with monoclonal anti- 
bodies (2AI) was done as described [9]. 
2.8. Other methods 
Protein measurements were performed by the 
methods of Lowry et al. [14] and by using the Bio- 
Rad protein measurement kit. Acid phosphatase 
activity was measured as described in [6]. SDS gel 
electrophoresis was performed according to Laem- 
mli [ 151. Lipoprotein electrophoresis was per- 
formed with a Redi-Disc kit (Miles, England). 
3. RESULTS 
We performed studies using affinity chroma- 
tography on gels containing covalently linked PAP 
to see whether the acid phosphatase has affinity 
for a specific serum protein. The gel was incubated 
with serum for 48 h and then transferred to a 
column. The column was washed with PBS until 
no protein could be demonstrated in the eluate 
(A&. Elution with 0.1 M Na acetate, pH 4.0, did 
not elute any further protein. With 0.1 M glycine 
HCl (pH 3.0) about 20% of the bound protein was 
recovered, whereas the main portion (80%) was 
eluted with 0.05 M HCl (pH 2.0). The immobilised 
PAP (8 mg) bound 0.2-1.4% (n = 20 purifica- 
tions) of the serum protein applied. When the 
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bound protein (0.7 mg) was reabsorbed on immo- 
bilised PAP, 95% of the protein applied was eluted 
only with 0.05 M HCl. The bound protein re- 
presented 5-18% of its total serum concentration. 
When the protein bound to PAP (PAP-BP) was 
subjected to HPLC, one main protein peak was 
evident. This protein was characterised by gel and 
lipoprotein electrophoreses, immunodiffusion and 
isoelectric focusing. In SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) the eluted protein 
was homogenous and had an M, of 27000-30000. 
In lipoprotein electrophoresis the protein had pre- 
,& mobility. 
Immunodiffusion using polyclonal monospe- 
cific antisera raised against apo AI, AII, AIV, B, 
E and several serum proteins, ai-antitrypsin, 
az-macroglobulin, Cs and Cd complements, Cr in- 
hibitor, acid al-glycoprotein, ceruloplasmin, 
hemopexin, transferrin, haptoglobin, IgA, IgD, 
IgE, IgG and IgM revealed that apo A-I was the 
only protein that could be demonstrated. Isoelec- 
Fig.1. Isoelectric focusing of the serum protein that 
binds to PAP. (A,B) Isoelectric focusing patterns as 
visualized by immunoblotting using a monoclonal anti- 
apo A-I antibody (2AI) of: lane 1, normal human serum 
(1~1); lane 2, protein eluted from the PAP-affinity 
column at pH 2.0. The faint precipitation line on B, lane 
2, below that of apo A-1-i corresponds to apo A-I-2. 
Lane 3, normal human serum (0.5 ~1). (C) Same gel as 
in B but stained for protein with Coomassie blue. 
tric focusing followed by immunoblotting with a 
monoclonal apo A-I antibody verified that the pro- 
tein was apo A-I (fig.1). It displayed a focusing 
pattern indistinguishable from that of plasma apo 
A-I. 
An antiserum against the affinity-purified PAP- 
binding protein was raised in rabbits. In im- 
munodiffusion this antiserum reacted with 
purified apo A-I but not with apo A-II, A-IV or E. 
A radioimmunoassay (RIA) was developed using 
this antiserum as the binder, and affinity-purified 
PAP-binding protein as the standard, and follow- 
ing iodination, as the label. With this technique 
purified apo A-I could be efficiently quantified 
(fig.2). From these data we conclude that the cir- 
culating PAP-binding protein is apo A-I. 
As acid phosphatase occurs in several iso-forms 
it was of interest o study whether LAP could also 
bind to apo A-I. Similar experiments to those 
described for PAP were therefore performed. Af- 
finity chromatography experiments using columns 
containing immobilised LAP revealed that LAP 
was also avidly bound to apo A-I. Immobilized 
LAP (0.8 mg) could bind 0.6 mg apo A-I from 
1.5 ml serum, which was 32% of its total serum 
concentration. When a gel containing immobilised 
apo A-I (0.3 mg) was incubated with serum con- 
taining a high concentration of LAP (6 g/l) 0.3 mg 
LAP was bound to the column and could be eluted 
only with 0.05 M HCl (pH 2.0). 
0.5 1.0 
APOPROTEIN A I (p9/ml) 
Fig.2. Relationship between the protein that binds PAP 
as measured by radioimmunoassay, and pure apo A-I. 
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4. DISCUSSION 
The high serum concentrations of LAP (1 .O g/l) 
and the high seminal fluid concentrations of PAP 
(1 g/l) suggest possible physiological roles for 
these enzymes. However, these roles remain 
unknown. This investigation shows that these two 
isoenzymes are avidly bound to a serum protein, 
apo A-I, the main protein constituent of HDL. 
Much interest has recently been focused on this 
lipoprotein fraction. Not only is HDL an indicator 
of the risk of coronary heart disease [16] but it has 
also been shown to accommodate acute-phase pro- 
teins [17] and endotoxins [ 181. Evidence has been 
reported that HDL are involved in the entry of 
cholesterol to steroidogenic and hepatic cells [19] 
and in the net movement of cholesterol out of cells 
[20-221. Despite the numerous functions that have 
been assigned to HDL little is known about its 
metabolism. 
Here, we describe a strong and specific binding 
of acid phosphatases to the main apoprotein of 
HDL, apo A-I. The physiological meaning of this 
association, if any, is at present an enigma. We 
would like to consider some possibilities. 
The interaction between apo A-I and the enzyme 
could be meaningful in the transport of acid 
phosphatases in plasma or in detoxifying the en- 
zymes as has been shown for endotoxins [18]. 
Another possibility is that the enzymes take part in 
the intravascular metabolism of HDL 
phospholipids, which turn over in HDL at least 
5-times faster than the apoproteins [23]. Apo A-I 
has been shown to be an effective activator of 
lecithin-cholesteryl acyltransferase (LCAT) [24]. It 
is not known whether apo A-I can also act as an ac- 
tivator of acid phosphatases in the metabolism of 
lipoprotein phospholipids. 
Finally, acid phosphatase could be involved in 
the interaction of HDL with cells. Tissues known 
to be rich in acid phosphatase, such as liver and 
kidney, have also been shown to take up apo A-I 
avidly [19,25]. It has also been demonstrated that 
HDL displays specific binding to placental cells 
[26] and testis membranes [27] but it is not known 
whether transfer of apo A-I to these cells occurs. 
Lysosomes play an important role in receptor- 
mediated endocytosis and catabolism of LDL [28]. 
That lysosomes also play an important role in the 
intracellular metabolism of apo A-I has been 
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shown using inhibitors of lysosomal enzymes 
[29,30]. In Tangier disease, a disorder characte- 
rized by the absence of normal HDL, these lipo- 
proteins are diverted to the lysosomal compart- 
ment and degraded [31]. Whether the interaction 
we have observed between apo A-I and the 
lysosomal enzyme, acid phosphatase, has any con- 
sequences for the intracellular transport of 
lipoproteins remains to be established. Our results 
support the finding that there are apo A-I contain- 
ing lipoproteins with pre-,& mobility [32]. 
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